MOTS-c peptide dosage chart for females: typical research ranges, injection frequency, and safety notes. Learn what's studied and what remains unknown.
There is no officially established MOTS-c peptide dosage chart for females, because MOTS-c is not approved as a drug for human use and regulators have not confirmed any safe or effective human dose. Published research uses a range of amounts in animals and cell models, and most charts circulating online are copied from rodent studies rather than clinical trials. Anyone considering MOTS-c should review it with a licensed healthcare professional instead of relying on a chart alone.
What MOTS-c Is and Why Female-Specific Dosing Is Unclear
MOTS-c is a mitochondrial-derived peptide encoded in the 12S ribosomal RNA region of mitochondrial DNA. Researchers study it for its role in metabolic regulation, insulin sensitivity, and exercise capacity.
Nearly all of the controlled dosing data comes from male rodents. Very few human studies exist, and those that do rarely publish a clear dose, schedule, or sex-based breakdown. That gap is why a female-specific MOTS-c dose cannot be stated with confidence.
MOTS-c is not FDA-approved for human use in the United States. Products sold online are typically labeled "for research use only," which means they have not been evaluated for purity, sterility, or safety in people.
Reported MOTS-c Research Ranges
The table below summarizes amounts reported in the scientific literature. These figures come from laboratory models and are not dosing recommendations for humans.
| Model | Route | Reported amount | Frequency | Notes |
|---|---|---|---|---|
| Rodent metabolic studies | Subcutaneous injection | 0.5 mg/kg | Daily for 4-8 weeks | Most commonly cited preclinical range |
| Rodent exercise studies | Subcutaneous or intraperitoneal | 0.5-1 mg/kg | Daily | Endpoints focused on endurance and glucose handling |
| Cell culture | In vitro | 1-10 µM | Not applicable | Cannot be converted to a human dose |
| Early human research | Varied or undisclosed | Not standardized | Not standardized | Small samples, limited published detail |
Researchers sometimes apply body-surface-area conversion to estimate a human equivalent from animal data. That math is a rough estimate only and has not been validated for MOTS-c, so it should never be treated as a clinical dose.
How to Read a MOTS-c Dosage Chart
When you find a mots-c dosage chart online, check these details before you trust any number on it:
- Unit: mg/kg, mcg, and mg are not interchangeable, and a missing unit is a red flag.
- Species: A mouse dose is not a human dose.
- Route: Subcutaneous, intraperitoneal, and oral exposures behave differently.
- Frequency and duration: A single-dose study says nothing about long-term use.
- Source: Look for a peer-reviewed citation, not a vendor blog.
- Population: Charts that never mention sex, age, or body weight leave out variables that matter.
A complete mots-c peptide dosage protocol should include the dose, route, timing, cycle length, monitoring plan, and stop criteria, not just a number.
Female-Specific Factors Worth Considering
No human study has shown that females need a different MOTS-c dose than males. Still, several variables can change how any peptide behaves in the body.
- Body composition and weight: Weight-based dosing scales with body mass, and average body mass differs between sexes.
- Hormonal status: Estrogen and progesterone can influence glucose metabolism and mitochondrial function.
- Menstrual cycle phase: Metabolic markers shift across the cycle, which complicates interpretation of any single measurement.
- Pregnancy and breastfeeding: MOTS-c has not been studied in pregnancy, and use during pregnancy or breastfeeding is not recommended.
- Medications and conditions: Diabetes, thyroid disorders, and prescription weight-loss drugs can interact with the metabolic pathways MOTS-c is thought to influence.
These factors are reasons for caution, not a formula for adjusting a dose on your own.
Peptide Charts People Often Confuse With MOTS-c
Searchers sometimes land on the wrong chart because peptide names and blends look similar.
| Peptide | Common research focus | Frequently charted range | Regulatory status in the US |
|---|---|---|---|
| MOTS-c | Metabolism, mitochondrial function | 0.5-1 mg/kg in rodent studies | Not FDA-approved for human use |
| Lipo-C | Fat-loss blends, often with B vitamins | Varies widely by formula | Not FDA-approved as a drug |
| Semaglutide | GLP-1 receptor, glucose and weight | 0.25-2.4 mg weekly | FDA-approved for specific indications |
| BPC-157 | Tissue repair research | 250-500 mcg in animal studies | Not FDA-approved for human use |
| PT-141 (bremelanotide) | Sexual desire | 1.75 mg as needed | FDA-approved for premenopausal women with HSDD |
| AOD 9604 | Fat metabolism research | 250-500 mcg in some studies | Not FDA-approved for weight loss |
If you are comparing fat-loss options, a lipo-c peptide dosage chart describes a compounded blend rather than a single peptide, so the numbers are not comparable to MOTS-c. Likewise, a semaglutide peptide dosage chart reflects an FDA-approved prescription drug with a slow titration schedule, not a research peptide.
People researching tissue-repair compounds often begin with a bpc-157 dosage chart by weight, which belongs to an entirely different area of study.
Safety, Sourcing, and Legal Status
MOTS-c is not FDA-approved for human use in the United States. It is not a lawful prescription product, and research-grade vials are not manufactured under pharmaceutical standards.
Specific risks include unknown purity, contamination, incorrect dosing, and injection-site reactions. There is also no long-term safety data in humans. Anyone with a metabolic condition, who is pregnant or breastfeeding, or who takes prescription medication should talk with a physician before considering any research peptide.
If a chart promises a specific "female dose" without citing human data, it is guessing.
Frequently Asked Questions
What is the recommended MOTS-c dosage for females?
There is no recommended MOTS-c dosage for females or males, because MOTS-c is not FDA-approved and no human dose has been established. Research amounts around 0.5 to 1 mg/kg come from rodent studies and should not be copied. A licensed clinician can discuss the risks, but no standard protocol exists.
Does MOTS-c have to be injected?
In animal research, MOTS-c is usually given by subcutaneous or intraperitoneal injection because peptides are broken down in the digestive tract. Human studies are limited and routes are not standardized. Any injection carries risks of infection and contamination when the product is not pharmaceutical-grade.
Does MOTS-c affect women differently than men?
There is no human evidence that women need a different MOTS-c dose than men. However, body weight, hormonal status, and menstrual cycle phase can affect metabolic measurements, which makes results harder to interpret. Pregnancy and breastfeeding are considered reasons to avoid it because no safety data exist.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.